Cergentis
Maya studied Biotechnology at the University of Barcelona and went on to get her Master's degree in Regenerative Medicine and Technology at the University of Utrecht. Afterwards, Maya did her PhD at the Hubrecht Institute in Eva van Rooij's lab where she focused on unraveling the molecular mechanisms underlying Hypertrophic Cardiomyopathy (HCM).
Maya joined Cergentis as International Sales Manager for Cell Line Development in January 2022.
Cergentis
1 followers
Cergentis' Targeted Locus Amplification (TLA) Technology uniquely enables the targeted complete Next Generation Sequencing of any genomic locus in any genome of interest.